文献速递白血病

初诊急性髓系白血病诱导化疗中伊达比星与大剂量柔红霉素的前瞻性随机比较

Prospective Randomized Comparison of Idarubicin and High-Dose Daunorubicin in Induction Chemotherapy for Newly Diagnosed Acute Myeloid Leukemia.
PubMed 文献 · J Clin Oncol · 2017-06-20

这项III期随机试验比较伊达比星(12 mg/m2/d×3天)与大剂量柔红霉素(90 mg/m2/d×3天)联合阿糖胞苷(200 mg/m2/d×7天)诱导治疗299例初诊急性髓系白血病年轻成人,完全缓解率、复发率与生存均无显著差异,但FLT3-ITD突变患者中大剂量柔红霉素组生存显著更优。

要点

  • 伊达比星组与大剂量柔红霉素组完全缓解率分别为80.5%与74.7%,无显著差异(P=.224)。
  • 中位随访34.9个月,4年总生存、无事件生存与复发累积发生率两组均无显著差异。
  • FLT3-ITD突变患者中,大剂量柔红霉素组总生存与无事件生存显著优于伊达比星组。

核心结论

  • 这项比较伊达比星与大剂量柔红霉素的III期试验未发现完全缓解率、复发和生存的显著差异。
  • 发现治疗组与FLT3-ITD突变存在显著交互作用,FLT3-ITD突变患者中大剂量柔红霉素比伊达比星更有效。

研究设计与样本

  • 前瞻性随机III期试验,共分析299例初诊急性髓系白血病年轻成人,149例随机分配至阿糖胞苷联合伊达比星组(AI),150例分配至阿糖胞苷联合大剂量柔红霉素组(AD)。
  • 所有患者接受阿糖胞苷200 mg/m2/d,共7天;伊达比星12 mg/m2/d,共3天;大剂量柔红霉素90 mg/m2/d,共3天。

主要发现

  • 232例(77.6%)获得完全缓解,AI组与AD组完全缓解率分别为80.5%与74.7%(P=.224)。
  • 中位随访34.9个月,AI组与AD组4年总生存率分别为51.1%与54.7%(P=.756)。
  • AI组与AD组复发累积发生率分别为35.2%与25.1%(P=.194)。
  • AI组与AD组无事件生存率分别为45.5%与50.8%(P=.772)。
  • 两臂毒性特征相似;FLT3-ITD突变患者中,AI组与AD组中位总生存分别为15.5个月与未达到(P=.030),无事件生存分别为11.9个月与未达到(P=.028)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Purpose We compared two induction regimens, idarubicin (12 mg/m2/d for 3 days) versus high-dose daunorubicin (90 mg/m2/d for 3 days), in young adults with newly diagnosed acute myeloid leukemia (AML). Patients and Methods A total of 299 patients (149 randomly assigned to cytarabine plus idarubicin [AI] and 150 assigned to cytarabine plus high-dose daunorubicin [AD]) were analyzed. All patients received cytarabine (200 mg/m2/d for 7 days). Results Complete remission (CR) was induced in 232 patients (77.6%), with no difference in CR rates between the AI and AD arms (80.5% v 74.7%, respectively; P = .224). At a median follow-up time of 34.9 months, survival and relapse rates did not differ between the AI and AD arms (4-year overall survival, 51.1% v 54.7%, respectively; P = .756; cumulative incidence of relapse, 35.2% v 25.1%, respectively; P = .194; event-free survival, 45.5% v 50.8%, respectively; P = .772). Toxicity profiles were also similar in the two arms. Interestingly, overall and event-free survival times of patients with FLT3 internal tandem duplication (ITD) mutation were significantly different (AI v AD: median overall survival, 15.5 months v not reached, respectively; P = .030; event-free survival, 11.9 months v not reached, respectively; P = .028). Conclusion This phase III trial comparing idarubicin with high-dose daunorubicin did not find significant differences in CR rates, relapse, and survival. Significant interaction between the treatment arm and the FLT3-ITD mutation was found, and high-dose daunorubicin was more effective than idarubicin in patients with FLT3-ITD mutation.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Lee JH, Kim H, Joo YD, et al. Prospective Randomized Comparison of Idarubicin and High-Dose Daunorubicin in Induction Chemotherapy for Newly Diagnosed Acute Myeloid Leukemia. J Clin Oncol. 2017. PMID: 28632487. doi:10.1200/JCO.2017.72.8618

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。